Use of yeast chemigenomics and coxen informatics in preclinical evaluation of anticancer agents

Neoplasia

Volumn 13, Issue 1, 2011, Pages 72-80

  Smith, Steven C ^a   Havaleshko, Dmytro M ^a   Moon, Kihyuck ^a   Baras, Alexander S ^a   Lee, Jae ^b   Bekiranov, Stefan ^a   Burke, Daniel J ^a   Theodorescu, Dan ^c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMIDACRINE; NSC 637993; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; FUNGAL GENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEDICAL INFORMATICS; MOUSE; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; TREATMENT RESPONSE;

EID: 78650975859     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.101214     Document Type: Article

References (46)

1. Botteman MF, Pashos CL, Redaelli A, Laskin B, and Hauser R (2003). The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21, 1315-1330.
2. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng A-C, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, et al. (2001). Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19, 666-675.
3. Gallagher DJ, Milowsky MI, and Bajorin DF (2008). Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the secondline setting. Cancer 113, 1284-1293.
4. Smith SC, Baras AS, Lee JK, and Theodorescu D (2010). The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res 70, 1753-1758.
5. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, Karpovich J, Grimshaw A, and Theodorescu D (2007). A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci USA 104, 13086-13091.
6. Williams PD, Cheon S, Havaleshko DM, Jeong H, Cheng F, Theodorescu D, and Lee JK (2009). Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res 69, 8302-8309.
7. Shoemaker RH (2006). The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6, 813-823.
8. Berger B, Marquardt H, and Westendorf J (1996). Pharmacological and toxicological aspects of new imidazoacridinone antitumor agents. Cancer Res 56, 2094-2104.
9. Burger AM, Jenkins TC, Double JA, and Bibby MC (1999). Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311. Br J Cancer 81, 367-375.
10. Skladanowski A, Plisov SY, Konopa J, and Larsen AK (1996). Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors. Mol Pharmacol 49, 772-780.
11. TM): the first of a potent new class of FLT3 inhibitors. AACR Meeting Abstracts 2006, B35.
12. Otake Y, Chau M, Ajami A, and Fernandes D (2007). Mechanism of topoisomerase II inhibition by the imidazoacridinone, C-1311. AACR Meeting Abstracts 2007, 4041.
13. Thomas A, Anthoney A, Ahmed S, Drouin M, Major A, Capizzi RL, Grieshaber C, Loadman P, and Twelves C (2006). Evaluation of the safety of C-1311 administered in a phase 1 dose-escalation trial as a 1-hour infusion once every 3 weeks in patients with advanced solid tumors. ASCO Meeting Abstracts 24, 12005.
14. Thomas AL, Anthoney A, Scott E, Ahmed S, Lundberg AS, Major A, Capizzi RL, and Twelves CJ (2008). C-1311, a novel inhibitor of FLT3 and topoisomerase II: a phase 1 trial of a once every three week schedule in patients with advanced solid tumors. J Clin Oncol 26, 2576.
15. Havaleshko DM, Cho H, Conaway M, Owens CR, Hampton G, Lee JK, and Theodorescu D (2007). Prediction of drug combination chemosensitivity in human bladder cancer. Mol Cancer Ther 6, 578-586.
16. Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L, and Grever MR (1995). In vivo cultivation of tumor cells in hollow fibers. Life Sci 57, 131-141.
17. Pan X, Yuan DS, Ooi S-L, Wang X, Sookhai-Mahadeo S, Meluh P, and Boeke JD (2007). dSLAManalysis of genome-wide genetic interactions in Saccharomyces cerevisiae. Methods 41, 206-221.
18. Pierce SE, Fung EL, Jaramillo DF, Chu AM, Davis RW, Nislow C, and Giaever G (2006). A unique and universal molecular barcode array. Nat Methods 3, 601-603.
19. Boyle EI, Weng S, Gollub J, Jin H, Botstein D, Cherry JM, and Sherlock G (2004). GO:TermFinder-open source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes. Bioinformatics 20, 3710-3715.
20. Blower PE, Yang C, Fligner MA, Verducci JS, Yu L, Richman S, and Weinstein JN (2002). Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data. Pharmacogenomics J 2, 259-271.
21. Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, Chary KK, Reimers MA, Scherf U, Kahn A, Dolginow D, et al. (2007). Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 6, 820-832.
22. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ Jr, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, et al. (1997). An informationintensive approach to the molecular pharmacology of cancer. Science 275, 343-349.
23. Shah MA and Schwartz GK (2001). Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 7, 2168-2181.
24. Kaelin WG Jr (2005). The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5, 689-698.
25. Parsons AB, Brost RL, Ding H, Li Z, Zhang C, Sheikh B, Brown GW, Kane PM, Hughes TR, and Boone C (2004). Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. Nat Biotechnol 22, 62-69.
26. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, et al. (2000). Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18, 3068-3077.
27. Galsky MD (2005). The role of taxanes in the management of bladder cancer. Oncologist 10, 792-798.
28. Entwistle RA, Winefield RD, Foland TB, Lushington GH, and Himes RH (2008). The paclitaxel site in tubulin probed by site-directed mutagenesis of Saccharomyces cerevisiae ß-tubulin. FEBS Lett 582, 2467-2470.
29. Simon R (2008). The use of genomics in clinical trial design. Clin Cancer Res 14, 5984-5993.
30. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, and Cordon-Cardo C (2006). Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24, 778-789.
31. Atiya AF (2005). Estimating the posterior probabilities using the K -nearest neighbor rule. Neural Comput 17, 731-740.
32. Als AB, Dyrskjot L, von der Maase H, Koed K, Mansilla F, Toldbod HE, Jensen JL, Ulhoi BP, Sengelov L, Jensen KM, et al. (2007). Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 13, 4407-4414.
33. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, and Chinnaiyan AM (2004). ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6, 1-6.
34. Isambert N, Campone M, Bourbouloux E, Drouin M, Major A, Loadman P, Capizzi R, Grieshaber C, and Fumoleau P (2006). Evaluation of the safety of C-1311 administered in a phase I dose-escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumors. ASCO Meeting Abstracts 24, 2069.
35. Konopa JK, Koba M, and Dyrcz A (2005). Interstrand crosslinking of DNA by C-1311 (Symadex) and other imidazoacridinones. AACR Meeting Abstracts 2005, 1382-a.
36. Nguyen HB, Duncan K, Fang X, Chau M, Ajami A, and Small D (2008). FLT3 inhibition of leukemia cells by C-1311 and its analogs. AACR Meeting Abstracts 2008, 4753.
37. Capizzi RL, Roman LA, Tjulandin S, Smirnova I, Manikhas A, Paterson JS, Major A, Lundberg AS, and Fumoleau P (2008). Phase II trial of C1311, a novel inhibitor of topoisomerase II in advanced breast cancer. J Clin Oncol 26, 1055.
38. Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L, and Grever MR (1995). In vivo cultivation of tumor cells in hollow fibers. Life Sci 57, 131-141.
39. Pierce SE, Fung EL, Jaramillo DF, Chu AM, Davis RW, Nislow C, and Giaever G (2006). A unique and universal molecular barcode array. Nat Methods 3, 601-603.
40. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, and Cordon-Cardo C (2006). Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24, 778-789.
41. Als AB, Dyrskjot L, von der Maase H, Koed K, Mansilla F, Toldbod HE, Jensen JL, Ulhoi BP, Sengelov L, Jensen KM, et al. (2007). Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 13, 4407-4414.
42. Farcomeni A (2008). A review of modern multiple hypothesis testing, with particular attention to the false discovery proportion. Stat Methods Med Res 17, 347-388.
43. Pawitan Y, Michiels S, Koscielny S, Gusnanto A, and Ploner A (2005). False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics 21, 3017-3024.
44. Berrar D, Bradbury I, and Dubitzky W (2006). Instance-based concept learning from multiclass DNA microarray data. BMC Bioinformatics 7, 73.
45. Horlings HM, van Laar RK, Kerst J-M, Helgason HH, Wesseling J, van derHoeven JJM, Warmoes MO, Floore A, Witteveen A, Lahti-Domenici J, et al. (2008). Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 26, 4435-4441.
46. Atiya AF (2005). Estimating the posterior probabilities using the K-nearest neighbor rule. Neural Comput 17, 731-740.